Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 48

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 48
---
 M.P.H. |     |                  | 552,000 |     |                  | 569,000 |
| Molly Henderson            |     |                  | 500,000 |     |                  | 515,000 |

Bonus Compensation Each named executive officer is eligible for an annual cash bonus based upon the achievement of certain corporate performance goals and objectives approved by our compensation committee. The bonus program is designed to be consistent with our compensation philosophy, supported by market data, and with an emphasis on pay-for-performance. Both qualitative and quantitative guidelines were established for purposes of evaluating performance relative to the corporate objectives during 2024. These performance objectives were used as a guide by the compensation committee in subjectively determining overall corporate performance as they represented those areas in which the named executive officers and our employees generally were expected to focus their efforts. The actual bonuses awarded in any year, if any, may be more or less than the target, depending on the achievement of corporate objectives and may also vary based on other factors at the discretion of the compensation committee. The bonus program is weighted 100% based on our corporate goals for our CEO and 90% and 10% based on our corporate goals and individual performance, respectively, for the other named executive officers. In February 2024, the compensation committee, with input from our CEO and the board of directors, established overall corporate goals against which the performance of our NEOs would be measured for the purpose of determining the 2024 bonus payments. In establishing the 2024 corporate goals, the compensation committee focused on objectives likely to bring both short-term and long-term stockholder value. For 2024, our corporate goals fell into the following categories: regulatory, clinical and manufacturing developments (25%); financial, operational and commercial goals (75%) and more specifically included significant items such as: • successful FDA approval for our Non-Erosive GERD new drug application; • end of the year cash balance targets; • targets related to written prescriptions in our first year of launch; and • total net product revenue for 2024. Although our corporate goals are intended to be achieved with significant effort, achievability is substantially uncertain, as a result, we do not expect every goal to be achieved in any given year.

<div align='center'>33</div>

For 2024, each bonus could be earned up to a maximum of 150% of the target. Bonus target amounts are set based on the executive’s total salary for the bonus year. The target amount of each NEOs bonus